JPS6133173A - アミジン化合物 - Google Patents
アミジン化合物Info
- Publication number
- JPS6133173A JPS6133173A JP15504584A JP15504584A JPS6133173A JP S6133173 A JPS6133173 A JP S6133173A JP 15504584 A JP15504584 A JP 15504584A JP 15504584 A JP15504584 A JP 15504584A JP S6133173 A JPS6133173 A JP S6133173A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- agent
- complement
- formula
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Amidine compound Chemical class 0.000 title description 9
- 239000002253 acid Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 48
- 239000003795 chemical substances by application Substances 0.000 abstract description 22
- 239000002753 trypsin inhibitor Substances 0.000 abstract description 6
- 101710081722 Antitrypsin Proteins 0.000 abstract description 5
- 230000000288 anti-kallikrein effect Effects 0.000 abstract description 5
- 230000001475 anti-trypsic effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 239000012048 reactive intermediate Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000003171 anti-complementary effect Effects 0.000 abstract 1
- 230000001407 anti-thrombic effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 206010018910 Haemolysis Diseases 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000035939 shock Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940012957 plasmin Drugs 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- ULKSSXOMKDEKPC-UHFFFAOYSA-N 6-hydroxynaphthalene-2-carboximidamide Chemical compound C1=C(O)C=CC2=CC(C(=N)N)=CC=C21 ULKSSXOMKDEKPC-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002391 anti-complement effect Effects 0.000 description 4
- 239000004019 antithrombin Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- FCEQRBOTYXIORK-UHFFFAOYSA-N 2-(diaminomethylideneamino)benzoic acid Chemical compound NC(=N)NC1=CC=CC=C1C(O)=O FCEQRBOTYXIORK-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 108010028774 Complement C1 Proteins 0.000 description 3
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 108060005987 Kallikrein Proteins 0.000 description 3
- 102000001399 Kallikrein Human genes 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 108010008730 anticomplement Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- WFABPBQYDVHJLE-UHFFFAOYSA-N (6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydroimidazol-1-ylamino)benzoate Chemical compound C1=CC2=CC(C(=N)N)=CC=C2C=C1OC(=O)C(C=C1)=CC=C1NN1CCN=C1 WFABPBQYDVHJLE-UHFFFAOYSA-N 0.000 description 1
- KOXSJXPPMBZTEE-UHFFFAOYSA-N (6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydroimidazol-1-ylamino)benzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1=CC2=CC(C(=N)N)=CC=C2C=C1OC(=O)C(C=C1)=CC=C1NN1CCN=C1 KOXSJXPPMBZTEE-UHFFFAOYSA-N 0.000 description 1
- NCVIXRFLZFTMOS-UHFFFAOYSA-N (6-carbamimidoylnaphthalen-2-yl) methanesulfonate Chemical compound C1=C(C(N)=N)C=CC2=CC(OS(=O)(=O)C)=CC=C21 NCVIXRFLZFTMOS-UHFFFAOYSA-N 0.000 description 1
- SKAWDTAMLOJQNK-UHFFFAOYSA-N 2-acetamido-3-(4-hydroxyphenyl)propanoic acid ethyl ester Chemical compound CCOC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 SKAWDTAMLOJQNK-UHFFFAOYSA-N 0.000 description 1
- GAVZNOLUZPCABT-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboximidamide Chemical compound NC(=N)c1c(O)ccc2ccccc12 GAVZNOLUZPCABT-UHFFFAOYSA-N 0.000 description 1
- DIWBCALLSGRDFG-UHFFFAOYSA-N 4-(4,5-dihydroimidazol-1-ylamino)benzoic acid;hydrochloride Chemical compound Cl.C1=CC(C(=O)O)=CC=C1NN1C=NCC1 DIWBCALLSGRDFG-UHFFFAOYSA-N 0.000 description 1
- KPUSGAIHMNZQOG-UHFFFAOYSA-N 4-(4,5-dihydroimidazol-1-ylamino)benzoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C(=O)O)=CC=C1NN1C=NCC1 KPUSGAIHMNZQOG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- YWAVLHZJMWEYTA-YDALLXLXSA-N ATEE Chemical compound O.CCOC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 YWAVLHZJMWEYTA-YDALLXLXSA-N 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- FJGXDMQHNYEUHI-LRFIHEIOSA-N alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FJGXDMQHNYEUHI-LRFIHEIOSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- SQTPLGZIJHJLSF-ZETCQYMHSA-N methyl (2s)-2-acetamido-5-(diaminomethylideneamino)pentanoate Chemical compound COC(=O)[C@@H](NC(C)=O)CCCN=C(N)N SQTPLGZIJHJLSF-ZETCQYMHSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15504584A JPS6133173A (ja) | 1984-07-25 | 1984-07-25 | アミジン化合物 |
| HU853727A HU195769B (en) | 1984-07-25 | 1985-07-12 | Process for the production of new amidin compounds and medecal preparatives containing thereof as active substance |
| PCT/JP1985/000392 WO1986000893A1 (en) | 1984-07-25 | 1985-07-12 | Novel amidine compounds |
| DE8585903394T DE3582057D1 (en) | 1984-07-25 | 1985-07-12 | Amidinverbindungen. |
| AU45492/85A AU567039B2 (en) | 1984-07-25 | 1985-07-12 | Novel amidine compounds |
| CA000486773A CA1254205A (en) | 1984-07-25 | 1985-07-12 | 6-amidino-2-naphthyl benzoate compounds |
| EP85903394A EP0190356B1 (en) | 1984-07-25 | 1985-07-12 | Novel amidine compounds |
| US06/835,853 US4777182A (en) | 1984-07-25 | 1985-07-12 | 6-Amidino-2-naphthyl 4-guanidinobenzoate derivatives and pharmaceutical composition containing them |
| KR1019860700140A KR870001087B1 (ko) | 1984-07-25 | 1985-07-12 | 아미딘 화합물의 제조방법 |
| DD85278877A DD235637A5 (de) | 1984-07-25 | 1985-07-23 | Verfahren zur herstellung von amidinverbindungen |
| PH32559A PH20585A (en) | 1984-07-25 | 1985-07-23 | Novel amidine compound |
| ES545482A ES8607218A1 (es) | 1984-07-25 | 1985-07-23 | Un procedimiento para preparar compuestos de amidina |
| ZA855552A ZA855552B (en) | 1984-07-25 | 1985-07-23 | Amidine compounds |
| CS855463A CS255891B2 (en) | 1984-07-25 | 1985-07-24 | Process for preparing new derivatives of amidine |
| MX206081A MX160912A (es) | 1984-07-25 | 1985-07-24 | Procedimiento para la preparacion de derivados de benzoato de 6-amidino-2-naftilo |
| DK096286A DK169069B1 (da) | 1984-07-25 | 1986-03-03 | 6-Amidino-2-naphthyl-4-amino-benzoat-derivater og farmaceutisk acceptable syreadditionssalte deraf |
| FI860904A FI78461C (fi) | 1984-07-25 | 1986-03-04 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara amidinfoereningar. |
| NO86860865A NO163954C (no) | 1984-07-25 | 1986-03-07 | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt amidinderivat. |
| KR1019860700140A KR860700250A (ko) | 1984-07-25 | 1986-03-10 | 신규 아미딘 화합물 |
| SU864027333A SU1456008A3 (ru) | 1984-07-25 | 1986-03-24 | Способ получени кислотно-аддитивных солей амидиновых соединений |
| US07/217,405 US4820730A (en) | 1984-07-25 | 1988-07-11 | 6-amino-2-naphthyl 4-gusnichinobenzoate derivatives and pharmaceutical composition containing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15504584A JPS6133173A (ja) | 1984-07-25 | 1984-07-25 | アミジン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6133173A true JPS6133173A (ja) | 1986-02-17 |
| JPH0461868B2 JPH0461868B2 (enrdf_load_stackoverflow) | 1992-10-02 |
Family
ID=15597463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15504584A Granted JPS6133173A (ja) | 1984-07-25 | 1984-07-25 | アミジン化合物 |
Country Status (19)
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996020706A1 (fr) * | 1995-01-05 | 1996-07-11 | Torii Pharmaceutical Co., Ltd. | Agent thrombolytique |
| WO1996020917A1 (fr) * | 1995-01-05 | 1996-07-11 | Torii Pharmaceutical Co., Ltd. | Derives d'ester d'amidinonaphtyle substitues |
| WO2001094299A1 (fr) * | 2000-06-08 | 2001-12-13 | Shizuoka Coffein Co., Ltd. | Derives de benzene |
| WO2006123674A1 (ja) * | 2005-05-17 | 2006-11-23 | Santen Pharmaceutical Co., Ltd. | アミン誘導体を有効成分として含む血管新生阻害剤 |
| EP2119440A1 (en) | 2005-05-17 | 2009-11-18 | Santen Pharmaceutical Co., Ltd. | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease |
| JPWO2014007326A1 (ja) * | 2012-07-04 | 2016-06-02 | 味の素株式会社 | ナファモスタットメシル酸塩の製造方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3824236C1 (enrdf_load_stackoverflow) * | 1988-07-16 | 1989-12-28 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg, De | |
| CA2032420A1 (en) * | 1989-12-22 | 1991-06-23 | Akira Okuyama | Guanidinobenzene derivatives |
| US5238964A (en) * | 1990-04-05 | 1993-08-24 | Torii & Co., Ltd. | Agent for treatment of cerebrovascular contraction |
| US5652237A (en) * | 1994-09-09 | 1997-07-29 | Warner-Lambert Company | 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes |
| KR100620935B1 (ko) | 1998-03-19 | 2006-09-13 | 브리스톨-마이어스스퀴브컴파니 | 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법 |
| WO2001077082A1 (fr) * | 1999-06-02 | 2001-10-18 | Torii Pharmaceutical Co., Ltd. | Derives de naphtalene |
| US20100063146A1 (en) * | 2006-11-07 | 2010-03-11 | Medof M Edward | Method for treating disorders related to complement activation |
| BR112013000626B1 (pt) | 2010-07-09 | 2019-11-26 | Bhv Pharma Inc | formulação farmacêutica e método para preparar uma forma de dosagem da mesma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57179146A (en) * | 1981-04-28 | 1982-11-04 | Torii Yakuhin Kk | Amidine compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4292429A (en) * | 1978-03-08 | 1981-09-29 | Ciba-Geigy Corporation | Imidazole urea and amido compounds |
| AU527371B2 (en) * | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JPS60130561A (ja) * | 1983-12-16 | 1985-07-12 | Torii Yakuhin Kk | アミジン誘導体およびそれを含む強心剤 |
-
1984
- 1984-07-25 JP JP15504584A patent/JPS6133173A/ja active Granted
-
1985
- 1985-07-12 DE DE8585903394T patent/DE3582057D1/de not_active Expired - Fee Related
- 1985-07-12 AU AU45492/85A patent/AU567039B2/en not_active Ceased
- 1985-07-12 US US06/835,853 patent/US4777182A/en not_active Expired - Fee Related
- 1985-07-12 EP EP85903394A patent/EP0190356B1/en not_active Expired - Lifetime
- 1985-07-12 HU HU853727A patent/HU195769B/hu not_active IP Right Cessation
- 1985-07-12 WO PCT/JP1985/000392 patent/WO1986000893A1/ja active IP Right Grant
- 1985-07-12 KR KR1019860700140A patent/KR870001087B1/ko not_active Expired
- 1985-07-12 CA CA000486773A patent/CA1254205A/en not_active Expired
- 1985-07-23 ES ES545482A patent/ES8607218A1/es not_active Expired
- 1985-07-23 PH PH32559A patent/PH20585A/en unknown
- 1985-07-23 DD DD85278877A patent/DD235637A5/de not_active IP Right Cessation
- 1985-07-23 ZA ZA855552A patent/ZA855552B/xx unknown
- 1985-07-24 CS CS855463A patent/CS255891B2/cs not_active IP Right Cessation
- 1985-07-24 MX MX206081A patent/MX160912A/es unknown
-
1986
- 1986-03-03 DK DK096286A patent/DK169069B1/da not_active IP Right Cessation
- 1986-03-04 FI FI860904A patent/FI78461C/fi not_active IP Right Cessation
- 1986-03-07 NO NO86860865A patent/NO163954C/no not_active IP Right Cessation
- 1986-03-10 KR KR1019860700140A patent/KR860700250A/ko active Granted
- 1986-03-24 SU SU864027333A patent/SU1456008A3/ru active
-
1988
- 1988-07-11 US US07/217,405 patent/US4820730A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57179146A (en) * | 1981-04-28 | 1982-11-04 | Torii Yakuhin Kk | Amidine compound |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996020706A1 (fr) * | 1995-01-05 | 1996-07-11 | Torii Pharmaceutical Co., Ltd. | Agent thrombolytique |
| WO1996020917A1 (fr) * | 1995-01-05 | 1996-07-11 | Torii Pharmaceutical Co., Ltd. | Derives d'ester d'amidinonaphtyle substitues |
| AU686104B2 (en) * | 1995-01-05 | 1998-02-05 | Torii Pharmaceutical Co., Ltd. | Substituted amidinonaphthyl ester derivatives |
| WO2001094299A1 (fr) * | 2000-06-08 | 2001-12-13 | Shizuoka Coffein Co., Ltd. | Derives de benzene |
| WO2006123674A1 (ja) * | 2005-05-17 | 2006-11-23 | Santen Pharmaceutical Co., Ltd. | アミン誘導体を有効成分として含む血管新生阻害剤 |
| EP2119440A1 (en) | 2005-05-17 | 2009-11-18 | Santen Pharmaceutical Co., Ltd. | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease |
| EP2143431A1 (en) | 2005-05-17 | 2010-01-13 | Santen Pharmaceutical Co., Ltd. | Protective agent for neurocyte comprising amidino derivative as active ingredient |
| EP2236136A1 (en) | 2005-05-17 | 2010-10-06 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor containing amine derivate as active ingredient |
| JPWO2014007326A1 (ja) * | 2012-07-04 | 2016-06-02 | 味の素株式会社 | ナファモスタットメシル酸塩の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK96286D0 (da) | 1986-03-03 |
| DD235637A5 (de) | 1986-05-14 |
| DE3582057D1 (en) | 1991-04-11 |
| FI860904A0 (fi) | 1986-03-04 |
| EP0190356A4 (en) | 1987-12-09 |
| AU4549285A (en) | 1986-02-25 |
| KR870001087B1 (ko) | 1987-06-04 |
| CS255891B2 (en) | 1988-03-15 |
| NO163954B (no) | 1990-05-07 |
| DK96286A (da) | 1986-03-03 |
| ZA855552B (en) | 1986-03-26 |
| FI78461B (fi) | 1989-04-28 |
| EP0190356A1 (en) | 1986-08-13 |
| NO860865L (no) | 1986-04-10 |
| MX160912A (es) | 1990-06-14 |
| EP0190356B1 (en) | 1991-03-06 |
| US4777182A (en) | 1988-10-11 |
| AU567039B2 (en) | 1987-11-05 |
| ES8607218A1 (es) | 1986-05-16 |
| JPH0461868B2 (enrdf_load_stackoverflow) | 1992-10-02 |
| ES545482A0 (es) | 1986-05-16 |
| US4820730A (en) | 1989-04-11 |
| FI860904A7 (fi) | 1986-03-04 |
| DK169069B1 (da) | 1994-08-08 |
| HUT42433A (en) | 1987-07-28 |
| HU195769B (en) | 1988-07-28 |
| FI78461C (fi) | 1989-08-10 |
| SU1456008A3 (ru) | 1989-01-30 |
| PH20585A (en) | 1987-02-20 |
| NO163954C (no) | 1990-08-15 |
| CA1254205A (en) | 1989-05-16 |
| WO1986000893A1 (en) | 1986-02-13 |
| CS546385A2 (en) | 1987-07-16 |
| KR860700250A (ko) | 1986-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4634783A (en) | Novel amidine compound | |
| SU1176832A3 (ru) | Способ получени амидиновых производных | |
| JPS6133173A (ja) | アミジン化合物 | |
| US4570006A (en) | Amidine compound, process for producing same and anti-complement agent comprising same | |
| JPH05504775A (ja) | トロンビンの阻害剤および基質 | |
| US4563527A (en) | Amidine compounds | |
| US4490388A (en) | Amidine compound and anticomplement agent comprising same | |
| KR100445094B1 (ko) | 페니실라민아미드유도체 | |
| JPH0259145B2 (enrdf_load_stackoverflow) | ||
| EP0369035A1 (en) | Agent for treating pancreatitis or the like | |
| JPS6122075A (ja) | アミジン誘導体 | |
| JPS5849358A (ja) | アミジン誘導体および抗補体剤 | |
| JPS648630B2 (enrdf_load_stackoverflow) | ||
| EP0486702A1 (en) | Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same | |
| JPS5841855A (ja) | アミジン化合物 | |
| JPS6360739B2 (enrdf_load_stackoverflow) | ||
| JPS6360738B2 (enrdf_load_stackoverflow) | ||
| JPH045269A (ja) | シクロヘキサンカルボンヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤 | |
| GB2162171A (en) | Amidine compounds | |
| JPS62111963A (ja) | ｐ−グアニジノ安息香酸チオフエニルエステル誘導体及びそれらを含有する医薬品 | |
| FR2568253A1 (fr) | Nouvelle amidine | |
| JPS61189255A (ja) | リジン誘導体及び抗プラスミン剤 |